Charles Schwab’s Cardiff Oncology CRDF Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-164,708
| Closed | -$267K | – | 3460 |
|
|
2026
Q1 | $267K | Sell |
164,708
-23,947
| -13% | -$49.2K | ﹤0.01% | 3265 |
|
|
2025
Q4 | $530K | Sell |
188,655
-660
| -0.3% | -$1.53K | ﹤0.01% | 3149 |
|
|
2025
Q3 | $390K | Hold |
189,315
| – | – | ﹤0.01% | 3236 |
|
|
2025
Q2 | $596K | Buy |
189,315
+19,341
| +11% | +$59K | ﹤0.01% | 3079 |
|
|
2025
Q1 | $534K | Buy |
169,974
+68,310
| +67% | +$270K | ﹤0.01% | 3058 |
|
|
2024
Q4 | $441K | Sell |
101,664
-19,629
| -16% | -$61.4K | ﹤0.01% | 3181 |
|
|
2024
Q3 | $324K | Buy |
121,293
+12,503
| +11% | +$29.5K | ﹤0.01% | 3272 |
|
|
2024
Q2 | $242K | Buy |
108,790
+92,391
| +563% | +$348K | ﹤0.01% | 3416 |
|
|
2024
Q1 | $87.6K | Hold |
16,399
| – | – | ﹤0.01% | 3317 |
|
|
2023
Q4 | $24.3K | Hold |
16,399
| – | – | ﹤0.01% | 3470 |
|
|
2023
Q3 | $22.8K | Hold |
16,399
| – | – | ﹤0.01% | 3502 |
|
|
2023
Q2 | $24.1K | Hold |
16,399
| – | – | ﹤0.01% | 3537 |
|
|
2023
Q1 | $27.1K | Hold |
16,399
| – | – | ﹤0.01% | 3466 |
|
|
2022
Q4 | $23K | Hold |
16,399
| – | – | ﹤0.01% | 3484 |
|
|
2022
Q3 | $26K | Hold |
16,399
| – | – | ﹤0.01% | 3456 |
|
|
2022
Q2 | $37K | Sell |
16,399
-86,744
| -84% | -$145K | ﹤0.01% | 3433 |
|
|
2022
Q1 | $256K | Buy |
103,143
+5,380
| +6% | +$19K | ﹤0.01% | 3262 |
|
|
2021
Q4 | $588K | Hold |
97,763
| – | – | ﹤0.01% | 3095 |
|
|
2021
Q3 | $652K | Buy |
97,763
+12,146
| +14% | +$76.3K | ﹤0.01% | 3053 |
|
|
2021
Q2 | $570K | Buy |
+85,617
| New | +$726K | ﹤0.01% | 3124 |
|
|
2020
Q4 | – | Sell |
-11,636
| Closed | -$166K | – | 3400 |
|
|
2020
Q3 | $166K | Buy |
+11,636
| New | +$76.8K | ﹤0.01% | 3207 |
|
|
2017
Q2 | – | Sell |
-491
| Closed | -$41K | – | 3108 |
|
|
2017
Q1 | $41K | Hold |
491
| – | – | ﹤0.01% | 3045 |
|
|
2016
Q4 | $75K | Hold |
491
| – | – | ﹤0.01% | 3056 |
|
|
2016
Q3 | $159K | Hold |
491
| – | – | ﹤0.01% | 2958 |
|
|
2016
Q2 | $161K | Hold |
491
| – | – | ﹤0.01% | 2995 |
|
|
2016
Q1 | $165K | Hold |
491
| – | – | ﹤0.01% | 2937 |
|
|
2015
Q4 | $191K | Hold |
491
| – | – | ﹤0.01% | 2970 |
|
|
2015
Q3 | $202K | Hold |
491
| – | – | ﹤0.01% | 2956 |
|
|
2015
Q2 | $359K | Buy |
+491
| New | +$348K | ﹤0.01% | 2799 |
|
Other funds holding CRDF
LCM
P
Charles Schwab's CRDF Position: Q2 2026 in Review
Charles Schwab sold out of Cardiff Oncology (CRDF) in Q2 2026, closing a stake of 164,708 shares — an estimated $267K sold.
Charles Schwab first reported a position in CRDF in Q2 2015 and held it in 29 quarters. The position peaked at $652K in Q3 2021. 104 funds tracked by Wall St. Rank hold CRDF as of Q2 2026.
- Charles Schwab reported no remaining Cardiff Oncology position as of Q2 2026 after selling out during the quarter.
- Charles Schwab sold 164,708 Cardiff Oncology shares in Q2 2026, an estimated $267K.
- Charles Schwab first reported a position in Cardiff Oncology in Q2 2015 and held it in 29 quarters.
- Charles Schwab's Cardiff Oncology position peaked at $652K in Q3 2021.
- 104 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2026.
Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.